Company: AZN
Filing Date: 2025-11-06
Form Type: 6-K
Source: 0001654954-25-012630
Chunk: 9

Company: ASTRAZENECA PLC
Filing Date: 2025-11-06
Form: 6-K
Chunk 9
---
 (treatment difference: -1.8 [ 95% CI: -2.5, -1.1],       
 p<0.0001) and was sustained through week 26 (treatment             
 difference: -2.1 [95% CI: -3.1, -1.1],                             
 p<0.0001).                                                         |

Sustainability

Sustainability highlights

For the third consecutive year, TIME Magazine recognised AstraZeneca as one of the World's Best Companies with the Company ranking at 43 out of 1,000 global companies and as the top pharmaceutical company in terms of sustainability transparency. AstraZeneca also secured fifth place in Sustainability Magazine's Top 250 World's Most Sustainable Companies 2025, affirming its status as a global leader in responsible business and pharmaceutical innovation.

AstraZeneca engaged on climate action, health systems resilience and health equity at the United Nations (UN) General Assembly High-Level Meeting on non-communicable diseases (NCDs) and Climate Week NYC in September through over 100 engagements. EVP Global Operations, IT and Chief Sustainability Officer Pam Cheng represented the private sector at the UN alongside governments, NGOs and academia, focusing on the need to tackle NCDs.

Chair Michel Demaré also joined a group of 25 global health leaders, including former heads of state and ministers, calling for action on this topic through an Open Letter in POLITICO, with a focus on the human, social and financial impacts of chronic disease and targeted solutions.

Sustainability impact

Climate and nature

- The Company focused on sustainable respiratory care at the European Respiratory Society (ERS), hosting a sustainability symposium, key engagements and running a sustainable booth with a living lung installation.

- The Company won a 2025 Freezer Challenge Award for the fourth time from My Green Lab and the International Institute for Sustainable Laboratories, recognised as the Top Organization in the biotech and pharmaceutical sector for energy savings and best-in-class cold storage management.

Health equity

- At EXPO 2025, the Company advanced priorities to transform lung health in Japan and Asia-Pacific through best practice sharing on screening and integrated disease management. The Company convened national and international government and clinical experts in lung cancer and COPD to further collaboration for high-risk patients and reduce mortality in Japan.

- AstraZeneca's Young Health Programme (YHP) received the ACE Award for Workforce Innovation and Global Impact at the Healthcare Businesswomen's Association's (HBA) annual conference, recognising how the programme